Business Wire

nurture.farm – a Digital Platform for Sustainable Agriculture Scales up to Become Part of the OpenAg™ Network

19.7.2021 09:33:00 EEST | Business Wire | Press release

Share

nurture.farm – a digital platform for growers, farming communities and food systems, is scaling and expanding its global reach as a part of the OpenAg™ network. The OpenAg™ network was conceived by UPL Ltd, a world leader in sustainable agriculture.

The nurture.farm platform fosters resilient farmers, making agriculture simple, profitable and sustainable for generations to come through technology-led solutions covering every step of the farming life cycle. nurture.farm, which was incubated by UPL, will operate as an open platform in the supply of products, innovation and mechanisation.

Dhruv Sawhney, COO and Business Head, nurture.farm said:

“The impact of nurture.farm on farming communities represents significant progress in advancing our mission to reimagine sustainability for agriculture across the world and help farmers secure a brighter future. Our digital platform is helping farming communities that are facing a number of competing external risks and challenges including variable weather patterns, financial insecurity, and lack of access to information and mechanisation. We are democratising technology, creating a shared infrastructure and uniting farmers and buyers under a global community committed to driving sustainability. We look forward to taking our revolutionary platform to new markets, as we endeavour to change the game for farmers and make food systems more sustainable.”

“We are pleased to welcome nurture.farm to the OpenAg™ network, and excited for the role they will play in our mission to unlock opportunities for farmers, food security and sustainable agriculture worldwide,” says Carlos Pellicer – COO, UPL Ltd. “By increasing accessibility to the solutions, technologies, and services that growers need to thrive, nurture.farm is creating a truly customer-centric ecosystem that delivers on the promise of shared prosperity and feeds sustainable growth for all.”

Through a holistic approach, nurture.farm has developed a comprehensive ecosystem of integrated solutions to increase accessibility, connectivity and resilience, and secure sustainable outcomes. The key solutions include:

  • farm – supports farmers at every step of the farming life cycle by driving precision agriculture at scale through crop health solutions, advisory services, farm level mechanisation & digitization.
  • retail – enables retailers & farmers to purchase authentic and high-quality agricultural input products (crop protection, seeds, farm equipment, feeds, and more).
  • trade – connects farmers and buyers through end-to-end traceability of sustainable practices, transparency of information, and convenient access to markets.
  • sustain – drives sustainable agriculture globally through regenerative practices and reward farmers for adopting them

Launched in early 2020, nurture.farm has since grown both in scale and impact, now supporting over 1 million farmers and 50,000 retailers on its digital platform, with over 2.5 million acres of farmland serviced. The platform has been well received by users across India, and several promising pilot projects are underway in other key markets including the U.S., South Africa, Brazil and Australia.

As a part of its mission to create sustainable food systems, nurture.farm is encouraging regenerative agriculture practices through its selection of products, services, and projects. It is driving numerous new programs, including stubble burning avoidance programs, biological products, carbon credits and reward programs to advance this mission.

Jai Shroff, Global CEO of UPL Ltd. said:

“nurture.farm is one of the most exciting initiatives within the OpenAg™ network, unlocking opportunities for farmers and food systems worldwide, delivering shared prosperity for our growers and their communities, and supporting environmental sustainability. The success of nurture.farm’s operations in India, as well as its pilot projects further afield, demonstrate the value creation the platform provides. I look forward to supporting nurture.farm’s further expansion and impact.”

Notes to Editors:

About UPL

UPL Ltd. (NSE: UPL & BSE: 512070) is a global provider of sustainable agriculture products & solutions, with annual revenue exceeding $5 billion. We are a purpose-led company. Through OpenAg™, UPL is focused on facilitating progress for the entire agricultural value chain. We are building a network that redefines the way an entire industry thinks and works – open to fresh ideas, innovative ways and new answers as we strive towards our mission to make every single food product more sustainable.

As one of the largest agriculture solutions companies worldwide, our robust portfolio consists of biologicals and traditional crop protection solutions with more than 13,600 registrations. We are present in more than 130 countries, represented by more than 10,000 colleagues globally. For more information about our integrated portfolio of solutions across the food value chain including seeds, post-harvest, as well as physical and digital services, please visit upl-ltd.com and follow us on LinkedIn, Twitter, Instagram and Facebook

About OpenAg

OpenAg™ is an open network to create sustainable growth for all – no limits, no borders. Together we are reimagining sustainability, bringing all of the different players across the food system – from farmers to food producers to consumers - in the spirit of collaboration to change how the whole industry thinks, works and evolves. Through agility, creativity and cooperation, and from new technologies, seeds, and biological solutions, to digital platforms, training programmes, and partnerships, OpenAg™ is an open door, an open heart, and an open invitation to work together to build sustainable, resilient, beneficial food systems.

To learn more about OpenAg™ visit upl-ltd.com/our-story/open-ag

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media relations:
pr@nurture.farm

Investor relations:
Radhika Arora
radhika.arora@upl-ltd.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 10:10:00 EEST | Press release

LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The

Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 10:00:00 EEST | Press release

Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 years, she has led global teams to achieve a 100% success rate from Phase 3 development through to FDA approval for multiple programs spanning oncology, immunology and respiratory medicine. In addition, she raised funds of around $400M as founder and CEO. Across her career she has contributed to 20 drug approvals, engaging

TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 10:00:00 EEST | Press release

Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network upgrades. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260803353435/en/ Adtran’s SDX 6400 Series is helping TOHKnet demonstrate how Japan’s operators can migrate to 50G PON without disrupting existing PON services. “As demand for digital services continues to grow, this trial is a key milestone for the future of fiber access in Jap

“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 10:00:00 EEST | Press release

The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the project continues to captivate audiences through its

Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 10:00:00 EEST | Press release

Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib, is a first-in-class oral dual-node PI3K/AKT/mTOR (PAM) pathway inhibitor, which selectively inhibits S6K and AKT1/3. Rupitasertib was purposefully and rationally designed to target S6K for potent PAM inhibition and AKT1/3 to block the AKT compensatory feedback loop, while sparing AKT2 to avoid hyperglycemia, which we believe will lead to a superior efficacy and safety profile compared to other PAM pathway inhibitors. Under the terms of the agreement, Roche will s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye